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Objective: Reports on zonisamide monotherapy are limited despite favourable preliminary data, and typically restricted to tertiary
referral centres. The goal of this study is to report clinical experience with zonisamide monotherapy in a large, multi-group
clinic setting.
Methods: We reviewed the charts of patients treated with zonisamide monotherapy in the Neurology Department of the
Kelsey-Seybold Clinic (Houston, Texas) during an 18-month period. We analysed subgroups of patients who were naive to
antiepileptic drug (AED) therapy (Group 1) and those who had previous exposure to AEDs (Group 2).
Results: The study included 54 paediatric and adult patients with a variety of seizure types: 15 patients in Group 1 and 39 patients
in Group 2. Mean maintenance zonisamide dosages in the two groups were similar (193 mg/day in Group 1 vs. 218 mg/day in
Group 2). Thirty-eight patients (70.4%) continued zonisamide monotherapy, with 7 patients (13.0%) adding a second AED and
9 patients (16.7%) switching to a different drug. Of the 24 patients who became seizure free on zonisamide monotherapy, 11
were on the 100-mg initial dosage. Zonisamide monotherapy was well tolerated.
Conclusions: Zonisamide monotherapy is safe and effective for a variety of seizure types and may be appropriate as first-line
therapy in some cases.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
The objective of pharmacotherapy for epilepsy is
to achieve maximum efficacy (seizure freedom)
with minimal or no adverse events (AEs). This
goal is best achieved using as few drugs as pos-
sible at the lowest dosages needed for effective
seizure management. Although polypharmacy may
be required for some patients to maintain accept-
able seizure control, it is often unnecessary and
sometimes detrimental. Shorvon and Reynolds1 suc-
cessfully reduced polypharmacy to monotherapy
in 29 of 40 consecutive epilepsy patients, often
noting a decrease in seizure frequency and/or im-
provement in cognitive function from the previous
year during which the subjects were on polyphar-
macy. Ludgate et al.2 showed that a reduction from
polypharmacy to monotherapy or reduced polyphar-
macy (i.e. fewer drugs) was associated with signif-
icantly better scores on several psychometric tests.
Although these studies were done before the intro-
duction of several of the newer antiepileptic drugs
(AEDs), some of the older and newer drugs cur-
rently in use are associated with significant cognitive
AEs3.
Zonisamide, a newer AED with multiple mech-
anisms of action, has demonstrated efficacy as an
adjunctive agent in clinical trials4–6. The drug is indi-
cated as an adjunctive therapy for partial seizures in
adults, but has been used in Japan since 1989 and in
the United States since 2000 for a variety of seizure
types in both adult and paediatric epilepsy patients.
Zonisamide monotherapy has been used successfully
in Japan for a number of years7. Recently, there have
been reports from Japan8 and the United States9 of
zonisamide monotherapy for infantile spasms. For
the most part, however, North American experience
with zonisamide monotherapy is limited and usu-
ally restricted to tertiary referral centres. Here, we
report our experience with zonisamide monotherapy
in the neurology department of a large, multi-group
clinic.
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METHODS
This chart review included all patients who received
zonisamide as monotherapy in the Neurology Depart-
ment of the Kelsey-Seybold Clinic (Houston, Texas)
between 1 April 2001 and 30 September 2002. Charts
were reviewed for patient demographic data, seizure
types, previous AED exposure, zonisamide dosage,
duration of treatment and clinical outcome. For the
purposes of this analysis, patients were divided into
two groups: those for whom zonisamide monotherapy
was their first treatment with an AED (Group 1) and
those who initiated zonisamide monotherapy after dis-
continuing other AEDs (Group 2).
RESULTS
Fifty-four patients were treated with zonisamide
monotherapy during the 18-month study period: 15 in
Group 1 and 39 in Group 2. Most patients in Group 2
had discontinued their previous AED therapy due to
lack of efficacy (19 patients) or AEs (18 patients). One
patient was switched to zonisamide after receiving a
different AED in the emergency department, and one
had been seizure free for more than 2 years without
pharmacotherapy but was started on zonisamide after
seizure recurrence. Patient demographics and seizure
types are presented in Table 1.
Patients in Group 1 were maintained on zonisamide
dosages of 100–400 mg/day, with a mean dosage of
193 mg/day. Patients in Group 2 received dosages of
100–500 mg/day, with a mean dosage of 218 mg/day.
Overall, 20 patients (37.0%) were maintained on the
initial dosage of 100 mg/day.
During the study period, 23 patients (42.6%) re-
ceived zonisamide monotherapy for less than 6
months, 21 patients (38.9%) for 6–12 months and 10
patients (18.5%) for longer than 12 months. Thirty-
eight patients (70.4%) continued zonisamide mono-
Table 1: Patient demographics and seizure types prior to
initiation of zonisamide monotherapy.
Group 1 Group 2
Number of patients 15 39
Male, n (%) 8 (53.3) 10 (25.6)
Female, n (%) 7 (46.7) 29 (74.4)
Mean (range) age in years 32.5 (13–72) 30.0 (12–63)
Seizure types,a n (%)
Simple partial 1 (6.7) 1 (2.6)
Complex partial 6 (40.0) 10 (25.6)
Generalised tonic–clonic 8 (53.3) 23 (59.0)
Secondarily generalised
tonic–clonic
3 (20.0) 6 (15.4)
Myoclonic 1 (6.7) 1 (2.6)
Absence 0 5 (12.8)
a Some patients experienced multiple seizure types.
Table 2: Zonisamide monotherapy in patients with and
without previous AED exposure.
Group 1, n (%) Group 2, n (%)
Duration of zonisamide
monotherapy
<6 months 6 (40.0) 17 (43.6)
6–12 months 7 (46.7) 14 (35.9)
>12 months 2 (13.3) 8 (20.5)
Continuing zonisamide
monotherapy
10 (66.7) 28 (71.8)
Second AED added 1 (6.7) 6 (15.4)
Discontinued zonisamide 4 (26.7) 5 (12.8)
Table 3: Patients who experienced seizure freedom on
zonisamide monotherapy by seizure type and dosage.
Seizure type(s) Dosage n
(mg/day)
Simple partial 100 1
200 1
Complex partial 100 3
200 2
300 2
Generalised tonic–clonic 100 5
200 2
300 3
Secondarily generalised tonic–clonic 100 1
200 1
Absence and generalised tonic–clonic 100 1
200 1
400 1
therapy (Table 2). Seven patients (13.0%) added a
second AED, and 9 patients (16.7%) replaced zon-
isamide with another AED. Reasons for zonisamide
discontinuation included recurrent seizures (2 pa-
tients), headache, body ache, anxiety, memory prob-
lems, and drowsiness (1 patient each), with 2 patients
discontinuing against medical advice because they
did not want to take any medications. No serious AEs
were noted.
A total of 24 patients (44.4%) were seizure free
for at least 6 months on zonisamide monotherapy. Of
these, 11 (45.8% of seizure-free patients, 20.4% of
all patients) were seizure free on the initial dosage of
100 mg/day (Table 3). Four patients in Group 1 and 10
patients in Group 2 were seizure free for 6–12 months.
Two patients in Group 1 and 8 patients in Group 2 were
seizure free for more than 1 year. Seizure frequency
data for patients who did not achieve seizure freedom
were not available.
DISCUSSION
Clinical studies have shown that a reduction in
polypharmacy may improve patient care. In particular,
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some patients experience improved seizure control1
and/or fewer cognitive and behavioural AEs1, 2 on
monotherapy than with multiple drugs. An additional
advantage of monotherapy is that potential interac-
tions between AEDs do not complicate the choice of
medications. Zonisamide is a logical choice to initiate
monotherapy because it does not inhibit or induce cy-
tochrome P450 enzymes3, 5, and therefore will not in-
terfere with the metabolism of potential add-on drugs,
should they become necessary. However, the potential
effect of add-on drugs on zonisamide concentrations
merits consideration. Furthermore, zonisamide can be
given once a day5, which improves compliance10.
The results of our 18-month study in the neu-
rology department of a large, multi-group clinic
indicate that zonisamide monotherapy is safe and
effective, either as first-line therapy or for patients
who experience poor seizure control or intolerable
AEs with other AEDs. The mean dosage in patients
with previous AED exposure was slightly higher
than that of AED-naive patients, possibly because
AED-refractory patients may have epilepsies that
are more difficult to treat with low dosages. How-
ever, 20% of patients in the study were seizure free
at the 100-mg/day introductory dosage. Our expe-
rience suggests that zonisamide monotherapy is a
viable option for many epilepsy patients, and may
be a reasonable choice for first-line therapy in some
cases.
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